EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Should Paxlovid be prescribed for patients with severe COVID‐19 in the late course of infection? A case report

Qiang Li, Yibo He, Jin Liu, Xiaozhao Lu, Ziyou Zhou, Yu Kang, Wanying Wu, Jielan Wu, Feng Wang, Yinghao Sun, Wei Wang, Chengyi Hui und 4 weitere

Medicine Advances · 2023

DOI: 10.1002/med4.12 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Medicine Advances, 2023. Verfasst von Qiang Li und 15 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The infection of the coronavirus disease 2019 (COVID‐19) is often accompanied by pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in patients with mild and normal pneumonia within 5 days from the symptom onset. Herein, we report a practically effective use of Paxlovid compensatively in patients with COVID‐19 and severe pneumonia after 5 days of infection in a typical case in China. In this case, a 75‐year‐old man was diagnosed with severe COVID‐19 complicated with a pulmonary bacterial infection. After treatment with oxygen inhalation, Cefoperazone‐sulbactam and ambroxol, fever and upper respiratory symptoms were alleviated, except for the Oxygenation index (OI) remaining worse, Coronavirus was detected as positive, and levels of interleukin‐6 remained high. Paxlovid was prescribed for 5 days subsequently though it was 14 days since symptom onset. Thereafter, the nucleic acid of the patient turned negative in 7 days and the symptoms resolved. This case showed that Paxlovid can be considered in patients with COVID‐19 and severe pneumonia even in the later course of infection in clinical practice in China.

Zitieren

APA

Li, Q., He, Y., Liu, J., Lu, X., Zhou, Z., Kang, Y., Wu, W., Wu, J., Wang, F., Sun, Y., Wang, W., Hui, C., Wei, W., Wen, M., Chen, J., & Liu, Y. (2023). Should Paxlovid be prescribed for patients with severe COVID‐19 in the late course of infection? A case report. Medicine Advances. https://doi.org/10.1002/med4.12

Vancouver

Li Q, He Y, Liu J, Lu X, Zhou Z, Kang Y, et al. Should Paxlovid be prescribed for patients with severe COVID‐19 in the late course of infection? A case report. Medicine Advances. 2023. doi:10.1002/med4.12

BibTeX
@article{Li2023,
  author = {Li, Qiang and He, Yibo and Liu, Jin and Lu, Xiaozhao and Zhou, Ziyou and Kang, Yu and Wu, Wanying and Wu, Jielan and Wang, Feng and Sun, Yinghao and Wang, Wei and Hui, Chengyi and Wei, Wenting and Wen, Miaoyun and Chen, Jingjing and Liu, Yong},
  title = {Should Paxlovid be prescribed for patients with severe COVID‐19 in the late course of infection? A case report},
  journal = {Medicine Advances},
  year = {2023},
  doi = {10.1002/med4.12}
}
Kostenlos starten →